| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/AJRCCM/144.3_PT_1.626 |
| P698 | PubMed publication ID | 1679981 |
| P2093 | author name string | A. E. Tattersfield | |
| A. F. Wisniewski | |||
| H. C. Gongora | |||
| P2860 | cites work | Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist | Q35171854 |
| Rapid method for measurement of bronchial responsiveness | Q36131697 | ||
| Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients | Q36187949 | ||
| Aerosol salbutamol administration by IPPB: lowest effective dose | Q36453585 | ||
| Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma | Q68155488 | ||
| Protection against allergen-induced asthma by salmeterol | Q68161063 | ||
| P433 | issue | 3 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 626-629 | |
| P577 | publication date | 1991-09-01 | |
| P1433 | published in | The American Review of Respiratory Disease | Q26839505 |
| P1476 | title | A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects | |
| A Single-dose Comparison of Inhaled Albuterol and Two Formulations of Salmeterol on Airway Reactivity in Asthmatic Subjects | |||
| P478 | volume | 144 |
| Q72996887 | A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study |
| Q77130637 | An overview of nine clinical trials of salmeterol in an asthmatic population |
| Q72793351 | Antiasthma drug delivery. What is on the horizon? |
| Q71822767 | Comparison of DiskusTMInhaler, a New Multidose Powder Inhaler, with DiskhalerTMInhaler for the Delivery of Salmeterol to Asthmatic Patients |
| Q41728781 | Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma |
| Q77929435 | Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease |
| Q67525282 | Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma |
| Q35563253 | Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma |
| Q63494166 | Effect of aging on the release of salbutamol sulfate from lipid matrices |
| Q34605338 | Exercise-induced asthma in children |
| Q71864060 | Inhaled Salmeterol and Albuterol in Asthmatic Patients Receiving High-dose Inhaled Corticosteroids |
| Q35187262 | Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma |
| Q74221057 | Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant? |
| Q40388175 | Long- versus short-acting beta 2-agonists. Implications for drug therapy |
| Q24241960 | Regular treatment with salmeterol for chronic asthma: serious adverse events |
| Q43723756 | Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours |
| Q34653402 | Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease |
| Q41563083 | Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma |
| Q36274692 | Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group |
Search more.